Edwards Lifesciences Corp Form S-8 November 08, 2013

As filed with the Securities and Exchange Commission on November 8, 2013

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

EDWARDS LIFESCIENCES CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation or Organization) **36-4316614** (I.R.S. Employer Identification No.)

One Edwards Way Irvine, California 92614 (Address, Including Zip Code, of Principal Executive Offices)

Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program

Edgar Filing: Edwards Lifesciences Corp - Form S-8

Edwards Lifesciences Corporation 2001 Employee Stock Purchase Plan for United States Employees

(Full Title of the Plan)

Michael A. Mussallem Chairman of the Board and Chief Executive Officer Edwards Lifesciences Corporation One Edwards Way Irvine, California 92614 (949) 250-2500

(Name, Address and Telephone Number, Including Area Code, of Agent for Service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer x

Accelerated filer o

Smaller reporting company o

Non-accelerated filer o

CALCULATION OF REGISTRATION FEE

Title of Securities To Be Registered	Amount To Be Registered		M C	roposed aximum Offering Price er Share		N A	Proposed Jaximum Aggregate Offering Price		nount Of gistration Fee	
Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program Common										
Stock, \$1.00 par value	1,500,000 shares	(1)	\$	62.715	(2)	\$	94,072,500	(2)	\$ 12,117	(2)(3)
2001 Employee Stock Purchase Plan for United States Employees Common Stock, \$1.00 par value	700,000 shares	(1)	\$	62.715	(2)	\$	43,900,500	(2)	\$ 5,655	(2)(3)
Total	2,200,000 shares	(1)				\$	137,973,000	(2)	\$ 17,772	(2)(3)

(1) This Registration Statement covers, in addition to the number of shares of Edwards Lifesciences Corporation, a Delaware corporation (the Company or the Registrant), common stock, par value \$1.00 per share (the Common Stock), stated above, options and other rights to purchase or acquire the shares of Common Stock covered by this Registration Statement and, pursuant to Rule 416 under the Securities Act of 1933, as amended (the Securities Act), an additional indeterminate number of shares, options and rights that may be offered or issued pursuant to the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program (the Long-Term Stock Program) and the Edwards Lifesciences Corporation 2001 Employee Stock Purchase Plan for United States Employees (the U.S. ESPP and, together with the Long-Term Stock Program, the Plans) as a result of one or more adjustments under the Plans to prevent dilution resulting from one or more stock splits, stock dividends or similar transactions.

(2) Pursuant to Securities Act Rule 457(h), the maximum offering price, per share and in the aggregate, and the registration fee were calculated based upon the average of the high and low prices of the Common Stock on November 6, 2013, as quoted on the New York Stock Exchange.

Edgar Filing: Edwards Lifesciences Corp - Form S-8

(3) Pursuant to Securities Act Rule 457(p), the \$8,050.30 remaining filing fee previously paid with respect to unsold securities that were registered pursuant to a Registration Statement on Form S-3 (Commission File No. 333-116634) initially filed by the Registrant on June 18, 2004, and carried forward on a Registration Statement on Form S-3 (Commission No. 333-155744) initially filed by the Registrant on November 26, 2008, is set off against the registration fee due for this Registration Statement. The additional \$9,721.70 (representing the difference between the total registration fee of \$17,772 and the \$8,050.30 set off against the registration fee due for this Registration Statement) has been paid with respect to the registration fee due for this Registration Statement.

The Exhibit Index for this Registration Statement is at page 7.

EXPLANATORY NOTE

This Registration Statement is filed by the Company to register additional securities issuable pursuant to the Plans and consists of only those items required by General Instruction E to Form S-8.

PART I

INFORMATION REQUIRED IN THE

SECTION 10(a) PROSPECTUS

The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Securities Act Rule 428(b)(1).

2

PART II

INFORMATION REQUIRED IN THE

REGISTRATION STATEMENT

Item 3.

Incorporation of Certain Documents by Reference

The following documents of the Company filed with the Securities and Exchange Commission (the Commission) are incorporated herein by reference:

(a) The Company s Annual Report on Form 10-K for its fiscal year ended December 31, 2012, filed with the Commission on February 28, 2013 (Commission File No. 001-15525);

(b) The Company s Quarterly Reports on Form 10-Q for its fiscal quarter ended March 31, 2013, filed with the Commission on May 6, 2013 (Commission File No. 001-15525), for its fiscal quarter ended June 30, 2013, filed with the Commission on August 6, 2013 (Commission File No. 001-15525), and for its fiscal quarter ended September 30, 2013, filed with the Commission on November 7, 2013 (Commission File No. 001-15525);

(c) The Company s Current Reports on Form 8-K, filed with the Commission on March 1, 2013, May 16, 2013, May 17, 2013, June 18, 2013, September 20, 2013, and October 3, 2013 (each, Commission File No. 001-15525);

(d) The Company s Registration Statements on Form S-8, filed with the Commission on March 22, 2000, June 9, 2003, August 5, 2005, May 9, 2008, August 2, 2010, and August 7, 2012 (Commission File Nos. 333-33054, 333-105961, 333-127260, 333-150810, 333-168462, and 333-183106, respectively); and

(e) The description of the Company s Common Stock contained in Post-Effective Amendment No. 1 to the Company s Registration Statement on Form 10 filed with the Commission on April 5, 2000 (Commission File No. 001-15525), and any other amendment or report filed for the purpose of updating such description.

All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act), prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement. Any

Edgar Filing: Edwards Lifesciences Corp - Form S-8

statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

Item 5. Interests of N

Interests of Named Experts and Counsel

The validity of the issuance of Common Stock registered hereby is passed on for the Company by Denise E. Botticelli. Ms. Botticelli is the Vice President, Associate General Counsel and Secretary of the Company and is compensated by the Company as an employee. Ms. Botticelli has participated in and holds awards granted under the Company s equity and long-term compensation plans, owns shares of Common Stock and is eligible to participate in the Plans.

Item 8.

Exhibits

See the attached Exhibit Index at page 7, which is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Form S-8 Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on November 7, 2013.

EDWARDS LIFESCIENCES CORPORATION

By:

/s/ Michael A. Mussallem Michael A. Mussallem Chief Executive Officer

POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoints Denise E. Botticelli and Aimee S. Weisner, and each of them, acting individually and without the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them individually, or their or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Michael A. Mussallem Michael A. Mussallem	Chairman of the Board and Chief Executive Officer (Principal Executive Officer)	November 7, 2013
/s/ Thomas M. Abate Thomas M. Abate	Corporate Vice President, Chief Financial Officer (Principal Financial and Accounting Officer)	November 7, 2013
Mike R. Bowlin	Director	

Signature		Title	Date
/s/ John T. Cardis John T. Cardis	Director		November 7, 2013
/s/ Robert A. Ingram Robert A. Ingram	Director		November 7, 2013
/s/ William J. Link William J. Link, Ph.D.	Director		November 7, 2013
/s/ Barbara J. McNeil Barbara J. McNeil, M.D., Ph.D.	Director		November 7, 2013
/s/ David E.I. Pyott David E.I. Pyott	Director		November 7, 2013
/s/ Wesley W. von Schack Wesley W. von Schack	Director		November 7, 2013

EXHIBIT INDEX

Exhibit Number	Description of Exhibit
4.1	Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program (filed as Appendix A to the Company s Proxy Statement filed with the Commission pursuant to Section 14(a) of the Exchange Act on March 29, 2013 (Commission File No. 001-15525) and incorporated herein by this reference).
4.2	Edwards Lifesciences Corporation 2001 Employee Stock Purchase Plan for United States Employees (filed as Appendix B to the Company s Proxy Statement filed with the Commission pursuant to Section 14(a) of the Exchange Act on March 29, 2013 (Commission File No. 001-15525) and incorporated herein by this reference).
5	Opinion of Counsel (opinion re legality).
23.1	Consent of PricewaterhouseCoopers LLP (consent of independent registered public accounting firm).
23.2	Consent of Counsel (included in Exhibit 5).
24	Power of Attorney (included in this Registration Statement under Signatures).

7